Senseonics See Few Barriers To Adoption For Their Implantable CGM
GLP-1 inhibitors and an ever-shrinking company ecosystem are not issues for the company, according to its CEO.
GLP-1 inhibitors and an ever-shrinking company ecosystem are not issues for the company, according to its CEO.